Thirty-five year old Tsadik is a visceral leishmaniasis (VL) patient who is also infected with HIV. He is gaunt, weak and tired, with sunken eyes. Each breath he takes is laboured. Tsadik lives in Abdurafi, a region of northwest Ethiopia that is characterized with high VL-HIV co-infection because VL is endemic….
Thursday, 23 August 2012, a sunny and very hot afternoon in West Pokot, Kenya: Dust devils circle into the air as pickup trucks packed with passengers drop off numbers of people, who all settle under a large tree in the village. This is where the community gathers for elders’ meetings. It is here that Nancy Chemluo recounts how kala azar affected two of her sons, and how she and her community changed their approach to seeking treatment.
It’s early on the morning of Thursday, 23 August 2012. We are at the Chemolingot Sub-district Hospital, where SSG&PM treatment is being administered to patients suffering from kala-azar (visceral leishmaniasis). In one of the wards, sitting on a hospital bed, is Lemarus Tebakwani Lukeno, a 23-year-old kala-azar patient, who has been undergoing treatment for five days.